Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC
Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Primary objective of this study is to allow access and evaluate the safety of crizotinib for
patients in Japan with advanced NSCLC harboring a translocation or inversion involving the
ROS1 oncogene.